190 (new). The method of 177-180 where said at least one chronic immune-mediated disorder comprises asthma and at least one autoimmune disease.

191 (new). The method of any one of claims 1, 14, 57, 66, 77, 79, 83, 85, 86, 93, or 96 where said at least one chronic immune-mediated disorder comprises at least one conventional organ specific autoimmune disorder and at least one rheumatic disease/connective tissue disease.

D2 cont'd

Remarks

The claims have been amended, and additional claims presented, in order to better protect Applicant's invention.

With regard to the amendment to claim 1, it is noted that in the specification, the term "hyperactive immune response" is used to encompass "asthma/allergies and autoimmune disease" (P21,L27-29).

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\ipc\a-c\clas\Classen1d\class1d.preamend3.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claim 1 has been amended as follows:

1 (amended). A safer method of immunization comprising

(I) determining whether an immunization schedule of one or more doses of one or more immunogens, which schedule protects against at least one infectious disease, may affect [affects] the incidence, prevalence, or frequency [or severity] of [a] at least one chronic immune-mediated disorder in at least one treatment group of mammals, relative to a control group of mammals, which comprises identifying [immunizing mammals in] at least one treatment group of mammals [with] which received one or more doses of one or more immunogens, according to said immunization schedule, and comparing the incidence, prevalence or frequency of said chronic immune-mediated disorder in [the] at least one treatment group, with that in [the] at least one control group;

where said chronic immune-mediated disorder is [diabetes] a hyperactive immune response, and said mammals are human;

wherein the control and treatment group differ by at least one of the following differences:

a) the presence of at least one immunogen in the schedule for one group and not the other;
b) a difference in the size of the dose of at least one immunogen administered to both groups;
c) a difference in the number of doses of at least one immunogen administered to both groups; or
d) a difference in the day of administration, relative to birth, of the first dose of at least one immunogen administered to both groups; and

wherein the effect of the schedule on the incidence, prevalence, or frequency of the disorder is observed at least one year after the first difference in immunization between the groups is manifest, and

(II) immunizing at least one mammal with said one or more immunogens according to an immunization schedule that appears safe regarding its possible effect on the incidence , prevalence, or frequency of at least one chronic immune mediated disorder.

Claims 38-43, 97-149, and 151-154 have been cancelled.
Claims 156-191 have been added.

G:\ipc\a-c\clas\Classen1d\class1d.preamend3.wpd